Published in Lancet on February 07, 1976
Assessment of extrapyramidal disorders. Br J Clin Pharmacol (1981) 1.86
Parkinson's disease. J Neurol Neurosurg Psychiatry (1994) 1.84
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry (2003) 1.58
Drug treatment in Parkinson's disease. Br Med J (Clin Res Ed) (1984) 1.30
Speech disorders of Parkinsonism: a review. J Neurol Neurosurg Psychiatry (1981) 1.29
Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa. J Neurol Neurosurg Psychiatry (1976) 1.22
Domperidone and levodopa in Parkinson's disease. Br J Clin Pharmacol (1984) 1.19
Drug treatment of Parkinson's disease. BMJ (1995) 1.19
Complexity of dopamine metabolism. Cell Commun Signal (2013) 1.06
Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J Clin Invest (1995) 1.02
Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. Proc Natl Acad Sci U S A (1999) 0.98
Myotatic reflexes and the on-off effect in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (1981) 0.93
The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years. J Neurol Neurosurg Psychiatry (1989) 0.89
Levodopa-induced dyskinesias and their management. J Neurol (2008) 0.89
Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. Neurochem Int (2008) 0.88
Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study. J Neurol Neurosurg Psychiatry (1986) 0.88
Pharmacological treatment of Parkinson's disease. Postgrad Med J (2000) 0.87
Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol (1987) 0.87
A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry (1994) 0.87
Treating Parkinson's disease in the 21st century: can stem cell transplantation compete? J Comp Neurol (2014) 0.86
High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats. Eur J Neurosci (2007) 0.86
Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse. J Neurol Neurosurg Psychiatry (1989) 0.85
Dopamine D₂/D₃ agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson's disease. ChemMedChem (2011) 0.85
Lessons from a remarkable family with dopa-responsive dystonia. J Neurol Neurosurg Psychiatry (1994) 0.84
Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? J Neural Transm (Vienna) (2013) 0.84
Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors Increased yield of dopamine cells is dependent on embryonic donor age. Brain Res Bull (2005) 0.83
Resolution of dyskinesia and the "on-off" phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment. Br Med J (Clin Res Ed) (1986) 0.83
The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. Br J Clin Pharmacol (1991) 0.83
Targeting the progression of Parkinson's disease. Curr Neuropharmacol (2009) 0.82
D-512 and D-440 as novel multifunctional dopamine agonists: characterization of neuroprotection properties and evaluation of in vivo efficacy in a Parkinson's disease animal model. ACS Chem Neurosci (2013) 0.82
A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease. J Neurol (2004) 0.81
Mesulergine in early Parkinson's disease: a double blind controlled trial. J Neurol Neurosurg Psychiatry (1986) 0.81
The high-affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson's disease. J Neurochem (2014) 0.80
Controlled release levodopa treatment of motor fluctuations in Parkinson's disease. J Neurol Neurosurg Psychiatry (1987) 0.80
The motor response to sequential apomorphine in parkinsonian fluctuations. J Neurol Neurosurg Psychiatry (1991) 0.79
Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial. J Neurol (2014) 0.78
Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. CNS Drugs (2013) 0.78
Subcutaneous apomorphine infusion in Parkinson's disease: does it have a role? Postgrad Med J (1994) 0.77
Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. J Neurol Neurosurg Psychiatry (1980) 0.77
L-3,4-dihydroxyphenylalanine-induced hypersensitivity simulating features of denervation. Proc Natl Acad Sci U S A (1977) 0.77
Parkinson's disease-associated melanin steal. Neuropsychiatr Dis Treat (2014) 0.76
Interaction of D₃ preferring agonist (-)-N⁶-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D₂L, D₂S, and D₃ receptors: potent stimulation of mitogen-activated protein kinases and G protein-coupled inward rectifier potassium channels. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.75
Dysarthria in individuals with Parkinson's disease: a protocol for a binational, cross-sectional, case-controlled study in French and European Portuguese (FraLusoPark). BMJ Open (2016) 0.75
Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model. Sci Rep (2016) 0.75
Parkinson's disease. Postgrad Med J (1992) 0.75
Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry (1991) 0.75
Drug treatment of Parkinson's disease. Dialogues Clin Neurosci (2004) 0.75
Plasma DOPA levels and growth hormone response to levodopa in parkinsomism. J Neurol Neurosurg Psychiatry (1977) 0.75
A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease. J Neurol Neurosurg Psychiatry (1990) 0.75
Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues. J Neural Transm (Vienna) (2017) 0.75
A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo. Neuropharmacology (2017) 0.75
Corticocortical inhibition in human motor cortex. J Physiol (1993) 8.92
Mitochondrial complex I deficiency in Parkinson's disease. Lancet (1989) 5.72
Electric and magnetic stimulation of human motor cortex: surface EMG and single motor unit responses. J Physiol (1989) 5.69
Servo action in the human thumb. J Physiol (1976) 4.93
Interhemispheric inhibition of the human motor cortex. J Physiol (1992) 4.77
Servo action in human voluntary movement. Nature (1972) 4.33
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03
Painful legs and moving toes. Brain (1971) 3.63
Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56
The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain (1994) 3.54
Writers' cramp-a focal dystonia. Brain (1982) 3.43
Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms. BMJ (1998) 3.41
Outcome of investigation of patients with presenile dementia. Br Med J (1972) 3.39
Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science (1990) 3.31
Stretch reflex and servo action in a variety of human muscles. J Physiol (1976) 3.29
Scope of a technique for electrical stimulation of human brain, spinal cord, and muscle. Lancet (1982) 3.26
The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology (1982) 3.26
Corticobasal degeneration. Brain (1989) 3.20
Stimulation of the human motor cortex through the scalp. Exp Physiol (1991) 3.16
Peripheral beta-adrenergic receptors concerned with tremor. Clin Sci (1967) 2.97
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med (1980) 2.81
Motor cortex stimulation in intact man. 2. Multiple descending volleys. Brain (1987) 2.77
Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol (1995) 2.76
Classification of dystonia. Adv Neurol (1998) 2.75
Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry (1988) 2.74
Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia? J Neurol Neurosurg Psychiatry (1976) 2.72
Human walking and higher-level gait disorders, particularly in the elderly. Neurology (1993) 2.65
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain (1992) 2.64
Manual motor performance in a deafferented man. Brain (1982) 2.63
The anatomical basis of symptomatic hemidystonia. Brain (1985) 2.60
Is the human stretch reflex cortical rather than spinal? Lancet (1973) 2.58
Movement disorders in multiple sclerosis. Mov Disord (1995) 2.53
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
The pathophysiology of primary dystonia. Brain (1998) 2.51
Pathophysiology of blepharospasm and oromandibular dystonia. Brain (1985) 2.50
A method of monitoring function in corticospinal pathways during scoliosis surgery with a note on motor conduction velocities. J Neurol Neurosurg Psychiatry (1986) 2.50
Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry (1988) 2.46
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (1990) 2.45
Changes in the response to magnetic and electrical stimulation of the motor cortex following muscle stretch in man. J Physiol (1991) 2.44
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Attitudes of families to some aspects of Huntington's chorea. Psychol Med (1979) 2.40
A study of hereditary essential tremor. Brain (1994) 2.37
Focal dystonia of the jaw and the differential diagnosis of unilateral jaw and masticatory spasm. J Neurol Neurosurg Psychiatry (1986) 2.37
'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain (1988) 2.36
Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology (1992) 2.36
Disturbance of sequential movements in patients with Parkinson's disease. Brain (1987) 2.30
Postural electromyographic responses in the arm and leg following galvanic vestibular stimulation in man. Exp Brain Res (1993) 2.30
Abnormalities in central motor pathway conduction in multiple sclerosis. Lancet (1984) 2.30
Isolated single motor units in human muscle and their rate of discharge during maximal voluntary effort. J Physiol (1971) 2.28
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1998) 2.22
Delay in the execution of voluntary movement by electrical or magnetic brain stimulation in intact man. Evidence for the storage of motor programs in the brain. Brain (1989) 2.19
The sensory mechanism of servo action in human muscle. J Physiol (1977) 2.18
Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. J Neurol Neurosurg Psychiatry (1976) 2.18
Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet (1997) 2.16
Hysteria--a neurologist's view. Psychol Med (1986) 2.12
Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem (1997) 2.10
Corticobasal degeneration. A clinical study of 36 cases. Brain (1994) 2.10
'Subcortical dementia': the neuropsychological evidence. Neuroscience (1988) 2.08
Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain (1995) 2.06
Ballistic flexion movements of the human thumb. J Physiol (1979) 2.06
Disruption of spatial organization and interjoint coordination in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy. Mov Disord (2000) 2.06
Reciprocal inhibition between the muscles of the human forearm. J Physiol (1984) 2.05
Relationship between plasma propranolol concentration and relief of essential tremor. J Neurol Neurosurg Psychiatry (1979) 2.04
Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord (1995) 2.03
Modulation of motor cortical excitability by electrical stimulation over the cerebellum in man. J Physiol (1991) 2.01
Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res (1995) 1.98
Motor cortex stimulation in intact man. 1. General characteristics of EMG responses in different muscles. Brain (1987) 1.98
Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet (1977) 1.96
Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder. Lancet (1994) 1.95
Performance of simultaneous movements in patients with Parkinson's disease. Brain (1986) 1.95
How common is dementia in Parkinson's disease? Lancet (1984) 1.93
Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodents. Psychopharmacologia (1975) 1.93
Idiopathic torsion dystonia (dystonia musculorum deformans). A review of forty-two patients. Brain (1974) 1.93
Percutaneous electrical stimulation of corticospinal pathways at the level of the pyramidal decussation in humans. Ann Neurol (1991) 1.93
Levodopa in hepatic coma. Lancet (1970) 1.92
Assessing tremor severity. J Neurol Neurosurg Psychiatry (1993) 1.92
Effect of vision and stance width on human body motion when standing: implications for afferent control of lateral sway. J Physiol (1993) 1.91
Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology (1982) 1.88
Scaling of the size of the first agonist EMG burst during rapid wrist movements in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (1986) 1.88
Assessment of extrapyramidal disorders. Br J Clin Pharmacol (1981) 1.86
Movement disorders following lesions of the thalamus or subthalamic region. Mov Disord (1994) 1.86
A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet (1973) 1.85
Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry (1986) 1.84
Different sites of action of electrical and magnetic stimulation of the human brain. Neurosci Lett (1987) 1.84
Botulinum toxin treatment of spasmodic torticollis. J R Soc Med (1992) 1.81
New observations on the normal auditory startle reflex in man. Brain (1991) 1.80
The stiff leg syndrome. J Neurol Neurosurg Psychiatry (1997) 1.80
Reticular reflex myoclonus: a physiological type of human post-hypoxic myoclonus. J Neurol Neurosurg Psychiatry (1977) 1.79
Natural history of idiopathic torsion dystonia. Adv Neurol (1976) 1.79
Observations on the reflex response to muscle vibration in man and its voluntary control. Brain (1969) 1.78
Mini-mental state examination in neurological patients. J Neurol Neurosurg Psychiatry (1984) 1.77
Anticipatory postural reflexes in Parkinson's disease and other akinetic-rigid syndromes and in cerebellar ataxia. Brain (1980) 1.77